NEW YORK, May 6, 2026, 09:59 (EDT)
- CVS Health bumped up its 2026 adjusted profit outlook after notching first-quarter revenue above $100 billion, with earnings coming in ahead of Wall Street’s expectations.
- Aetna reported its medical benefit ratio at 84.6%, down from 87.3% the previous year. That figure reflects the portion of premiums allocated to medical care.
- CVS shares jumped roughly 9% at the open in New York, pushing managed-care stocks further into recovery.
CVS Health Corporation bumped its full-year profit outlook higher on Wednesday after posting a solid first quarter, with Aetna’s reduced medical costs and stronger revenue across its healthcare businesses doing much of the lifting. The company now sees 2026 adjusted earnings per share coming in between $7.30 and $7.50, compared with its previous view of $7.00 to $7.20.
CVS is under the microscope right now. Investors are waiting to see if leadership can regain control at Aetna after a string of health-insurance missteps, climbing Medicare Advantage expenses, and this year’s executive churn. Reuters reported that CVS posted its fifth consecutive quarterly earnings beat.
CVS shares jumped to $88.21 early in New York, gaining $7.52, or roughly 9.3%. That early surge pushed the stock past other managed-care names in the opening hour.
CVS turned in $100.43 billion in first-quarter revenue—a 6.2% increase from last year. GAAP diluted earnings per share landed at $2.30. Adjusted EPS, which excludes certain costs and accounting impacts, climbed to $2.57 versus $2.25 a year ago.
Chief Executive David Joyner pointed to “strong execution across our enterprise” as the reason behind CVS’s “positive performance,” according to the company release. CVS lifted its guidance thanks to improvements in Health Care Benefits and Pharmacy & Consumer Wellness. Still, the company said it’s sticking with “a cautious view” heading into the rest of the year, citing persistently high cost trends. CVS Health Investor Relations
Aetna tipped the scales this quarter. CVS reported its Health Care Benefits segment delivered $3.04 billion in adjusted operating income—jumping 52.6% year-over-year. The medical benefit ratio dropped to 84.6%. That number matters: the lower it goes, the more premium revenue CVS keeps after covering claims.
“We’re improving our capability of forecasting, so the cost trend did not surprise me,” Chief Financial Officer Brian Newman told Reuters. Leerink analyst Michael Cherny described it as “overall a very strong quarter,” adding this should back the recent momentum as CVS moves to rebuild earnings power. Reuters
CVS’s Health Services segment—which bundles in its pharmacy benefit manager Caremark—delivered $48.24 billion in revenue, a jump of 11%. That PBM business handles prescription-drug benefits for insurers and employers. Profit in the unit still dropped 7.1%. CVS pointed to improved client pricing, though that was partly countered by a more favorable drug mix and stronger purchasing economics.
The story wasn’t as tidy in retail pharmacy. Pharmacy & Consumer Wellness revenue ended up almost unchanged at $31.99 billion, but adjusted operating income dropped 8.8%. CVS blamed the hit on reimbursement pressures, higher business investments, lighter seasonal illness trends, and disruptions from weather. Prescription volume did catch a lift after picking up Rite Aid assets.
The big issue hanging over the sector: Medicare Advantage. CVS’s Aetna operation, along with UnitedHealth and Humana, offers private Medicare coverage targeting seniors and some disabled Americans. Back in April, the Centers for Medicare & Medicaid Services projected a 2.48% bump in 2027 Medicare Advantage payments—more than $13 billion in new funding. Even so, with claims usage running high, insurers are on edge about whether those rates will actually be enough.
The quarter doesn’t rule out risks. Should medical use tick higher, or pharmacy reimbursement get squeezed further, CVS’s margin pressure could intensify—unless it tweaks benefits, prices, or costs. In its most recent 10-Q, the company flagged no major updates to existing risk factors. Those same issues could still hit results, cash flow, or even the share price.
